Blue Planet Prize 2025: Announcement of Prize Laureates
TOKYO, Japan:
This year marks the 34th awarding of the Blue Planet Prize, the international environmental award sponsored by the Asahi Glass Foundation, chaired by Takuya Shimamura. Every year, the Foundation selects two laureates, individuals, or organizations who have made significant contributions to the resolution of global environmental problems. The Board of Directors has selected the following 2025 Blue Planet Prize laureates.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603602267/en/
Professor Robert B. Jackson (USA)
1. Professor Robert B. Jackson (USA) Born on September 26, 1961
Department of Earth System Science, Stanford University
Professor Robert B. Jackson is an expert on the carbon cycle in terrestrial ecosystems, including forests, grasslands, and wetlands. He has conducted pioneering research on the relationship between soil, vegetation, and soil bacterial communities. In addition, he has quantified the balance of greenhouse gases, such as carbon dioxide, methane, and nitrous oxide, from natural ecosystems and from fossil fuel use. Since 2017, he has served as chair of the Global Carbon Project (GCP), leading efforts to monitor and reduce greenhouse gas emissions.
2. Dr. Jeremy Leggett (UK) Born on March 16, 1954Founder and CEO of Highlands Rewilding Ltd.
Inaugural chairman of the Carbon Tracker Initiative
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
3 days ago
- Business Upturn
NetraMark Founder Coauthors New Publication on AI/ML Use in Clinical Trials, Alongside Authors From Leading Global Regulatory Organizations
TORONTO, June 12, 2025 (GLOBE NEWSWIRE) — NetraMark Holdings Inc. (the 'Company' or 'NetraMark') (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence (AI) solutions company transforming clinical trial design in the pharmaceutical industry through streamlined access to actionable analytics uncovered by AI, today announced that NetraMark founder Dr. Joseph Geraci was the lead author on a new publication that outlines the market opportunity for AI/ML to improve data quality and patient outcomes in clinical development. This manuscript, now available in the Journal of the Society for Clinical Data Management (JSCDM), is titled 'Current Opportunities for the Integration and Use of AI/ML in Clinical Trials: Good Clinical Practice Perspectives .' It identifies the ideal conditions and prerequisites for the use of emerging AI applications in clinical trials and the importance of aligning these technologies with Good Clinical Practice (GCP). Dr. Joseph Geraci, Founder, CSO, and CTO of NetraMark, contributed to this collaborative effort alongside individuals affiliated with organizations such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Danish Medicines Agency (DKMA), Pfizer, Sanofi, Neurocrine Biosciences, Saama Technologies, Relation Therapeutics, Cognizant Technology Solutions, and Wega Informatik AG. These contributions represent the personal views of the authors and not the official positions of their respective organizations. Drawing on the collective insights of regulators, sponsors, and technology developers, this publication explores the multifaceted landscape of AI/ML applications, where AI can deliver measurable benefits while ensuring compliance, transparency, patient safety, efficiency, accuracy, and overall effectiveness of clinical trials, specifically through seven real-world use cases: Smart Data Query Data Attributability Challenges in Wearable Device Data Enhancing Protocol Deviation Trending External Control Arms Streamlining Complaint Handling Patient Stratification in Diagnosis Patient Enrichment for Placebo/Drug Response Additionally, the manuscript highlights several challenges and ethical considerations facing AI/ML adoption in clinical trial, including: Challenges Generalizability – how well AI models can perform beyond their original training, testing, and validation data Provenance – the decisions, implicit or hidden, that were made in the creation of a model Effective clinical trialist-AI/ML interaction Ethical Considerations Robust, multi-layered privacy controls Trustworthy AI that is lawful, ethical, and technically and socially robust Built for Compliance, Designed for Impact: How NetraAI's Capabilities Align with Industry Needs Built from the ground up to advance the impact that AI can have on clinical trial enrichment, NetraAI goes beyond traditional AI assessments to provide a specialized solution for small or sparse dataset modeling, addressing the key conclusions of the JSCDM manuscript: Explainability and Auditability Data Quality Monitoring and Anomaly Detection Patient Stratification and Enrichment Mitigation of Placebo Response Multi-modal Data Integration Explainability and Auditability Ethical and Regulatory Alignment 'It was an honor to contribute to this significant review alongside respected voices from across the global regulatory and pharmaceutical landscape,' said Dr. Joseph Geraci, Founder, CSO, and CTO of NetraMark. 'NetraMark is committed to working with sponsors to realize the benefits of AI/ML adoption in traditional clinical trial processes. Our collective work underscores the opportunities for NetraAI to help set the standards in the pharmaceutical industry and establish the best use of AI/ML and ethical compliance for clinical trial evolution.' This review is available to the public at . About NetraMark NetraMark is a company focused on being a leader in the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the Pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that NetraMark can work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. Forward-Looking Statements This press release contains 'forward-looking information' within the meaning of applicable Canadian securities legislation including statements regarding the potential use of NetraMark's AI solutions to drive intelligent, patient-centric clinical trial optimization, the optimization of clinical trials by uncovering hidden patient subpopulations, how NetraAI may address the key conclusions of the JSCDM manuscript, the integration of NetraMark's AI as a dedicated solution to advance clinical trial success, NetraMark's commitment to working with sponsors to realize the benefits of AI/ML adoption in traditional clinical trial processes, opportunities for NetraAI to help set standards in the pharmaceutical industry, the establishment of best practices for AI/ML use and ethical compliance, and the advancement of technological capabilities of clinical trial enrichment, which are based upon NetraMark's current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as 'expect', 'likely', 'may', 'will', 'should', 'intend', 'anticipate', 'potential', 'proposed', 'estimate' and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions 'may', 'would' or 'will' happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. The forward-looking statements are expectations only and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results of the Company or industry results to differ materially from future results, performance or achievements. Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, NetraMark does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for NetraMark to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements as set out in the materials we file with applicable Canadian securities regulatory authorities on SEDAR+ at including our Management's Discussion and Analysis for the year ended September 30, 2024. These risk factors and other factors could cause actual events or results to differ materially from those described in any forward-looking information. The CSE does not accept responsibility for the adequacy or accuracy of this release. Contact Information: Swapan Kakumanu – CFO | [email protected] | 403-681-2549 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Yahoo
3 days ago
- Yahoo
DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting
Châtillon, France, June 11, 2025 DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the 'Company'), held its Combined General Meeting (the 'General Meeting'). The General Meeting was chaired by Michel de Rosen, Chairman of the Company. The Company's shareholders approved all resolutions submitted by the Board of Directors. The resolutions and the voting results are posted on the Investors/Annual General Meetings section of the Company's website: About DBV TechnologiesDBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary technology platform, Viaskin™, to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT™), the Viaskin platform is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual's underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin's immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company's food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age). DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company's ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company's ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309). For more information, please visit and engage with us on X (formerly Twitter) and LinkedIn. Viaskin and EPIT are trademarks of DBV Technologies. Investor Contact Katie MatthewsDBV Media ContactAngela Marcucci DBV Attachment PDF VersionFehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Business Upturn
4 days ago
- Business Upturn
Blue Planet Prize 2025: Announcement of Prize Laureates
TOKYO, Japan: This year marks the 34th awarding of the Blue Planet Prize, the international environmental award sponsored by the Asahi Glass Foundation, chaired by Takuya Shimamura. Every year, the Foundation selects two laureates, individuals, or organizations who have made significant contributions to the resolution of global environmental problems. The Board of Directors has selected the following 2025 Blue Planet Prize laureates. This press release features multimedia. View the full release here: Professor Robert B. Jackson (USA) 1. Professor Robert B. Jackson (USA) Born on September 26, 1961 Department of Earth System Science, Stanford University Professor Robert B. Jackson is an expert on the carbon cycle in terrestrial ecosystems, including forests, grasslands, and wetlands. He has conducted pioneering research on the relationship between soil, vegetation, and soil bacterial communities. In addition, he has quantified the balance of greenhouse gases, such as carbon dioxide, methane, and nitrous oxide, from natural ecosystems and from fossil fuel use. Since 2017, he has served as chair of the Global Carbon Project (GCP), leading efforts to monitor and reduce greenhouse gas emissions. 2. Dr. Jeremy Leggett (UK) Born on March 16, 1954Founder and CEO of Highlands Rewilding Ltd. Inaugural chairman of the Carbon Tracker Initiative
